Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This study will test the effectiveness of lisdexamfetamine (LDX) medication as a maintenance
therapy for the treatment of binge-eating disorder (BED) in patients with obesity. This is a
controlled test of whether, amongst responders to acute treatments, LDX medication results in
superior maintenance and longer-term outcomes compared with placebo.